Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved
如果获得批准,Acumen Pharmicals与Lonza合作,涵盖用于阿尔茨海默氏病的Sabirnetug(ACU193)的制造,用于临床开发和商业化